BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Quintiles, dabl to advance cardiovascular safety

October 5, 2012 | News | By BioSpectrum Bureau

Quintiles, dabl team to advance cardiovascular safety assessment



Singapore: Quintiles andÃ?Â dabl, a provider of centralized ambulatory blood pressure measurement (ABPM) services, have entered into a strategic alliance by whichÃ?Â Quintiles' customers worldwide will have access to dabl's round-the-clock ABPM services to enhance the safety and efficacy of global clinical trials across the entire trial lifecycle.

"dabl's scientific leadership and data management techniques are setting new industry standards and complement Quintiles' pioneering cardiac safety solutions," said Dr Deepa Desai, executive director, cardiac safety services, Quintiles. "Together we can improve understanding of drug-induced blood pressure responses and help our customers improve trial participant safety, manage risk, and improve efficiency - all vital to meet the challenges of the New Health."

The US FDA and other regulatory agencies are requiring assessment of 24-hour blood pressure (BP) profiles for BP-lowering drugs. There is also increased focus on how non-cardiovascular drugs affect blood pressure. The web-based dabl ABPM system automatically checks data in accordance with the study protocol; generates alerts about safety and enrollment issues and provides real-time access to clinical data and progress reports.

Professor Eoin O'Brien, medical director, dabl, said that, "Accuracy of circadian measurement, speed and excellence in interpreting data have never been more important in the clinical trial process. Biopharma companies will be able to make faster and more confident decisions about the cardiovascular effects of their compounds with the combination of Quintiles' therapeutic expertise and dabl's proprietary technology and excellence in providing haemodynamic profiles."

Mr W J Rickard, CEO, dabl, said that, "We welcome this alliance with Quintiles. It's another milestone in our development, particularly in our rapidly growing Global Clinical Trial Division."